Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Common Equity (2019 - 2025)

Biodesix's Common Equity history spans 7 years, with the latest figure at -$2.5 million for Q4 2025.

  • For Q4 2025, Common Equity fell 111.81% year-over-year to -$2.5 million; the TTM value through Dec 2025 reached -$2.5 million, down 111.81%, while the annual FY2025 figure was -$2.5 million, 111.81% down from the prior year.
  • Common Equity reached -$2.5 million in Q4 2025 per BDSX's latest filing, down from -$1.7 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $36.4 million in Q1 2021 to a low of -$7.0 million in Q2 2023.
  • Average Common Equity over 5 years is $11.0 million, with a median of $7.7 million recorded in 2022.
  • The largest YoY upside for Common Equity was 2026.49% in 2024 against a maximum downside of 220.92% in 2024.
  • A 5-year view of Common Equity shows it stood at $19.7 million in 2021, then rose by 4.46% to $20.6 million in 2022, then tumbled by 77.77% to $4.6 million in 2023, then surged by 355.81% to $20.9 million in 2024, then crashed by 111.81% to -$2.5 million in 2025.
  • Per Business Quant, the three most recent readings for BDSX's Common Equity are -$2.5 million (Q4 2025), -$1.7 million (Q3 2025), and $1.1 million (Q2 2025).